Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials ...

Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...

Regeneron Pharmaceuticals (REGN) is down more than -17% to lead losers in the S&P 500 and Nasdaq 100 after its itepekimab, an ...

The S&P 500 Index ($SPX) (SPY) today is down -0.40%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.23%, and the ...

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

U.S. stock futures were little changed Friday ahead of key inflation data, while shares in Asia ended lower and European ...

--On pace for largest percent decrease since Oct. 27, 2023, when it fell 19.13% --Down 9.68% month-to-date; on pace for worst month since Oct. 2023, when it fell 15.64% --Down 16.48% from its all-time ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...